[1]董丹妮,楚 翘,项 密,等.肺癌病人合并肌少症研究进展[J].肠外与肠内营养杂志,2024,(03):184-188192.[doi:DOI : 10.16151/j.1007-810x.2024.03.010]
　DONG Dan-ni,CHU Qiao,XIANG Mi,et al.Research progress on sarcopenia in patients with lung cancer[J].PARENTERAL & ENTERAL NUTRITION,2024,(03):184-188192.[doi:DOI : 10.16151/j.1007-810x.2024.03.010]
点击复制

肺癌病人合并肌少症研究进展()
分享到：

《肠外与肠内营养》杂志[ISSN:1007-810X/CN:32-1477/R]

卷:
期数:
2024年03期
页码:
184-188192
栏目:
综述
出版日期:
2024-06-10

文章信息/Info

Title:
Research progress on sarcopenia in patients with lung cancer
作者:
董丹妮; 楚 翘; 项 密; 何亚平
上海交通大学医学院公共卫生学院，上海 200025
Author(s):
DONG Dan-ni;  CHU Qiao;  XIANG Mi;  HE Ya-ping
School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
关键词:
肺癌 ; 肌少症 ; 预后 ; 身体活动 ; 生活质量
Keywords:
Lung cancer;  Sarcopenia;  Clinical outcomes;  Physical activity;  Quality of life
分类号:
R734.2，R685
DOI:
DOI : 10.16151/j.1007-810x.2024.03.010
文献标志码:
A
摘要:
肌少症是一种与肌肉量减少、肌力下降、躯体功能减退相关的综合征。由于肿瘤代谢、系统性炎症反应、疾病进展和治疗副作用导致身体活动降低等多重因素，肺癌病人肌少症发生风险高于一般人群，且与临床预后密切相关，是死亡率的独立预测因子，并严重影响生活质量和心理情绪。本文系统综述了肺癌病人合并肌少症的影响因素、临床预后及对生活质量和心理情绪的负面影响和干预手段。鉴于合并肌少症对肺癌病人的重要影响，亟待探索多学科联合干预模式以改善其生存状态和生活质量。
Abstract:
Sarcopenia is a syndrome associated with decreased muscle mass, decreased muscle strength, andreduced physical performance. Due to multiple factors such as tumor metabolism, systemic inflammatory response,disease progression, and reduced physical activity associated with treatment itself, the risk of sarcopenia in patients withlung cancer is higher than that of the general population. Sarcopenia is closely related to the clinical outcomes, includingincreased risk for mortality, and significantly impacts patients’long-term quality of life and mental health. This studysystematic reviewed the risk factors for sarcopenia in patients with lung cancer, its negative effects on clinical outcomes,long-term quality of life and mental health, and the interventions for sarcopenia. Given the significant impact ofsarcopenia on patients with lung cancer, it is urgent to explore a multidisciplinary intervention model to improve theirsurvival and quality of life.

参考文献/References:


[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020:GLOBOCAN Estimates of Incidence and Mortality Worldwidefor 36 Cancers in 185 Countries. CA: a Cancer Journal ForClinicians, 2021, 71(3): 209-249.
[2] Papadopoulou SK. Sarcopenia: A Contemporary Health Problemamong Older Adult Populations. Nutrients, 2020, 12(5): 1293.
[3] Nishioka N, Uchino J, Hirai S, et al. Association of Sarcopeniawith and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-SmallCell Lung Cancer. J Clin Med, 2019, 8(4): 450.
[4] Lin TY, Chen YF, Wu WT, et al. Impact of sarcopenia on theprognosis and treatment of lung cancer: an umbrella review.Discov Oncol, 2022, 13(1): 115.
[5] Nipp RD, Fuchs G, El-Jawahri A, et al. Sarcopenia Is Associatedwith Quality of Life and Depression in Patients with AdvancedCancer. Oncologist, 2018, 23(1): 97-104.
[6] 刘 娟, 丁清清, 周白瑜, 等. 中国老年人肌少症诊疗专家共识(2021). 中华老年医学杂志, 2021, 40(8): 943-952.
[7] Chen LK, Woo J, Assantachai P, et al. Asian Working Group forSarcopenia: 2019 Consensus Update on Sarcopenia Diagnosisand Treatment. Journal of the American Medical DirectorsAssociation, 2020, 21(3): 300-307.
[8] Auyeung TW, Arai H, Chen LK, et al. Letter to the editor:Normative data of handgrip strength in 26344 older adults - apooled dataset from eight cohorts in Asia. J Nutr Health Aging,2020, 24(1): 125-126.
[9] Yao J, Wang Y, Yang L, et al. Prevalence of possible sarcopenia incommunity-dwelling older Chinese adults: a cross-sectionalstudy. BMJ Open, 2022, 12(12): e067425.
[10] Xin C, Sun X, Lu L, et al. Prevalence of sarcopenia in olderChinese adults: a systematic review and meta-analysis. BMJOpen, 2021, 11(8): e041879.
[11] Surov A, Wienke A. Prevalence of sarcopenia in patients withsolid tumors: A meta-analysis based on 81, 814 patients. JPEN JParenter Enteral Nutr, 2022, 46(8): 1761-1768.
[12] Fearon K, Strasser F, Anker SD, et al. Definition andclassification of cancer cachexia: an international consensus.Lancet Oncol, 2011, 12(5): 489-495.
[13] Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines onnutrition in cancer patients. Clin Nutr, 2017, 36(1): 11-48.
[14] Queiroz AL, Dantas E, Ramsamooj S, et al. Blocking ActRIIBand restoring appetite reverses cachexia and improves survival inmice with lung cancer. Nat Commun, 2022, 13(1): 4633.
[15] Gomes M, Teixeira AL, Coelho A, et al. The role of inflammationin lung cancer. Adv Exp Med Biol, 2014, 816 :1-23.
[16] Molfino A, Iannace A, Colaiacomo MC, et al. Cancer anorexia:hypothalamic activity and its association with inflammation andappetite-regulating peptides in lung cancer. J CachexiaSarcopenia Muscle, 2017, 8(1): 40-47.
[17] Gupta D, Lis CG. Pretreatment serum albumin as a predictor ofcancer survival: a systematic review of the epidemiologicalliterature. Nutr J, 2010, 9: 69.
[18] Guttridge DC, Mayo MW, Madrid LV, et al. NF-kappaB-inducedloss of MyoD messenger RNA: possible role in muscle decay andcachexia. Science, 2000, 289(5488): 2363-2366.
[19] Op den Kamp CM, Langen RC, Minnaard R, et al. Pre-cachexiain patients with stages I-III non-small cell lung cancer: systemicinflammation and functional impairment without activation ofskeletal muscle ubiquitin proteasome system. Lung Cancer, 2012,76(1): 112-117.
[20] Makino T, Noguchi Y, Yoshikawa T, et al. Circulating interleukin6 concentrations and insulin resistance in patients with cancer. BrJ Surg, 1998, 85(12): 1658-1662.
[21] Borst SE. The role of TNF-alpha in insulin resistance. Endocrine,2004, 23(2-3): 177-182.
[22] Wang X, Hu Z, Hu J, et al. Insulin resistance accelerates muscleprotein degradation: Activation of the ubiquitin-proteasomepathway by defects in muscle cell signaling. Endocrinology,2006, 147(9): 4160-4168.
[23] Winter A, MacAdams J, Chevalier S. Normal protein anabolicresponse to hyperaminoacidemia in insulin-resistant patients withlung cancer cachexia. Clin Nutr, 2012, 31(5): 765-773.
[24] McCormick R, Vasilaki A. Age-related changes in skeletalmuscle: changes to life-style as a therapy. Biogerontology, 2018,19(6): 519-536.
[25] McLean JB, Moylan JS, Andrade FH. Mitochondria dysfunctionin lung cancer-induced muscle wasting in C2C12 myotubes.Front Physiol, 2014, 5: 503.
[26] 张 浩, 杨新官, 何 涌. 肌少症与晚期非小细胞肺癌临床病理特征及预后的相关性分析 . 实用肿瘤学杂志, 2022, 36(3):214-219.
[27] Kim CR, Kim EY, Kim YS, et al. Histologic subtypes are notassociated with the presence of sarcopenia in lung cancer. PloSOne, 2018, 13(3): e0194626.
[28] Gr?nberg BH, Valan CD, Halvorsen T, et al. Associationsbetween severe co-morbidity and muscle measures in advancednon-small cell lung cancer patients. J Cachexia SarcopeniaMuscle, 2019, 10(6): 1347-1355.
[29] Yang M, Shen Y, Tan L, et al. Prognostic Value of Sarcopenia inLung Cancer: A Systematic Review and Meta-analysis. Chest,2019, 156(1): 101-111.
[30] Li D, Tan X, Yuan H, et al. Usefulness of 18 F-FDG PET/computed tomography metabolic parameters in predictingsarcopenia and prognosis of treatment-naive patients with nonsmall cell lung cancer. Nucl Med Commun, 2023, 44(4): 309-317.
[31] Meijer TWH, Schuurbiers OCJ, Kaanders JHAM, et al.Differences in metabolism between adeno- and squamous cellnon-small cell lung carcinomas: spatial distribution andprognostic value of GLUT1 and MCT4. Lung Cancer, 2012, 76(3): 316-323.
[32] Thai AA, Solomon BJ, Sequist LV, et al. Lung cancer. Lancet(London, England), 2021, 398(10299): 535-554.
[33] Ushitani Y, Shimada Y, Yamada Y, et al. Clinical Impact ofSarcopenia 1 Year After Surgery for Patients with Early-StageNon-small Cell Lung Cancer. Ann Surg Oncol, 2022, 29(11):6922-6931.
[34] Moreira-Pais A, Ferreira R, Gil da Costa R. Platinum-inducedmuscle wasting in cancer chemotherapy: Mechanisms andpotential targets for therapeutic intervention. Life Sci, 2018, 208:1-9.
[35] Kinsey E, Ajazi E, Wang X, et al. Predictors of Physical andFunctional Loss in Advanced-Stage Lung Cancer PatientsReceiving Platinum Chemotherapy. J Thorac Oncol, 2018, 13(9):1294-1301.
[36] Kiss N, Beraldo J, Everitt S. Early Skeletal Muscle Loss in NonSmall Cell Lung Cancer Patients Receiving Chemoradiation andRelationship to Survival. Support Care Cancer, 2019, 27(7): 2657-2664.
[37] Op den Kamp CMH, De Ruysscher DKM, van den Heuvel M, etal. Early body weight loss during concurrent chemo-radiotherapyfor non-small cell lung cancer. J Cachexia Sarcopenia Muscle,2014, 5(2): 127-137.
[38] Kakinuma K, Tsuruoka H, Morikawa K, et al. Differences inskeletal muscle loss caused by cytotoxic chemotherapy andmolecular targeted therapy in patients with advanced non-smallcell lung cancer. Thorac Cancer, 2018, 9(1): 99-104.
[39] Bozzetti F. Chemotherapy-Induced Sarcopenia. Curr TreatOptions Oncol, 2020, 21(1): 7.
[40] Roch B, Coffy A, Jean-Baptiste S, et al. Cachexia - sarcopenia asa determinant of disease control rate and survival in non-smalllung cancer patients receiving immune-checkpoint inhibitors.Lung Cancer, 2020, 143: 19-26.
[41] Teba PP, Esther MG, Raquel SG. Association between physicalactivity and patient-reported outcome measures in patients withlung cancer: a systematic review and meta-analysis. Quality ofLife Research : an International Journal of Quality of LifeAspects of Treatment, Care and Rehabilitation, 2022, 31(7): 1963-1976.
[42] Kong S, Shin S, Lee JK, et al. Association between Sarcopeniaand Physical Function among Preoperative Lung Cancer Patients.J Pers Med, 2020, 10(4): 166.
[43] Nishimura JM, Ansari AZ, D’Souza DM, et al. ComputedTomography-Assessed Skeletal Muscle Mass as a Predictor ofOutcomes in Lung Cancer Surgery. Ann Thorac Surg, 2019, 108(5): 1555-1564.
[44] Deng HY, Hou L, Zha P, et al. Sarcopenia is an independentunfavorable prognostic factor of non-small cell lung cancer aftersurgical resection: A comprehensive systematic review and metaanalysis. Eur J Surg Oncol, 2019, 45(5): 728-735.
[45] 田文泽, 尤振兵, 张明志, 等. 肌少症对食管鳞癌围手术期临床结局的影响. 中华消化外科杂志, 2023, 22(11):1322-1329.
[46] Kawaguchi Y, Hanaoka J, Ohshio Y, et al. Sarcopenia increasesthe risk of post-operative recurrence in patients with non-smallcell lung cancer. PloS One, 2021, 16(9): e0257594.
[47] de Jong C, Chargi N, Herder GJM, et al. The association betweenskeletal muscle measures and chemotherapy-induced toxicity innon-small cell lung cancer patients. J Cachexia SarcopeniaMuscle, 2022, 13(3): 1554-1564.
[48] Bozzetti F. Forcing the vicious circle: sarcopenia increasestoxicity, decreases response to chemotherapy and worsens withchemotherapy. Ann Oncol, 2017, 28(9): 2107-2118.
[49] Matsuo Y, Mitsuyoshi T, Shintani T, et al. Impact of low skeletalmuscle mass on non-lung cancer mortality after stereotactic bodyradiotherapy for patients with stage I non-small cell lung cancer. JGeriatr Oncol, 2018, 9(6): 589-593.
[50] Tahir I, Marquardt JP, Mercaldo ND, et al. Utility ofNoncancerous Chest CT Features for Predicting Overall Survivaland Noncancer Death in Patients With Stage I Lung CancerTreated With Stereotactic Body Radiotherapy. AJR Am JRoentgenol, 2022, 219(4): 579-589.
[51] Hirsch L, Bellesoeur A, Boudou-Rouquette P, et al. The impact ofbody composition parameters on severe toxicity of nivolumab.Eur J Cancer, 2020, 124: 170-177.
[52] Wang J, Cao L, Xu S. Sarcopenia affects clinical efficacy ofimmune checkpoint inhibitors in non-small cell lung cancerpatients: A systematic review and meta-analysis. IntImmunopharmacol, 2020, 88: 106907.
[53] Chang KV, Hsu TH, Wu WT, et al. Is sarcopenia associated withdepression? A systematic review and meta-analysis ofobservational studies. Age Ageing, 2017, 46(5): 738-746.
[54] Xue D, Li N, Li L, et al. Sarcopenia is an independent risk factorfor depression in patients with advanced lung cancer. SupportCare Cancer, 2022, 30(11): 9659-9665.
[55] Zou HB, Yan XL, Dong WX, et al. Sarcopenia is a predictivefactor of poor quality of life and prognosis in patients after radicalgastrectomy. Eur J Surg Oncol, 2021, 47(8): 1976-1984.
[56] Wang B, Thapa S, Zhou T, et al. Cancer-related fatigue andbiochemical parameters among cancer patients with differentstages of sarcopenia. Support Care Cancer, 2020, 28(2): 581-588.
[57] 崔 华, 王朝晖, 吴剑卿, 等. 老年人肌少症防控干预中国专家共识(2023). 中华老年医学杂志, 2023, 42(02): 144-153.
[58] 宋春花, 王昆华, 郭增清, 等. 中国常见恶性肿瘤患者营养状况调查. 中国科学:生命科学, 2020, 50(12): 1437-1452.
[59] Gibney E, Elia M, Jebb SA, et al. Total energy expenditure inpatients with small-cell lung cancer: results of a validated studyusing the bicarbonate-urea method. Metabolism, 1997, 46(12):1412-1417.
[60] Cereda E, Turri A, Klersy C, et al. Whey protein isolatesupplementation improves body composition, muscle strength,and treatment tolerance in malnourished advanced cancer patientsundergoing chemotherapy. Cancer Med, 2019, 8(16): 6923-6932.
[61] Vega OM, Abkenari S, Tong Z, et al. Omega-3 PolyunsaturatedFatty Acids and Lung Cancer: nutrition or Pharmacology? NutrCancer, 2021, 73(4): 541-561.
[62] 刘 莲, 俞 静. ω-3多不饱和脂肪酸在非小细胞肺癌病人中的应用. 肠外与肠内营养, 2016, 23(02): 112-115.
[63] 陈 冲, 王文君, 叶小群. Omega-3多不饱和脂肪酸在非小细胞肺癌病人中应用的研究进展 . 肠外与肠内营养, 2023, 30(03):185-188+192.
[64] Cortiula F, Hendriks LEL, van de Worp WRPH, et al. Physicalexercise at the crossroad between muscle wasting and theimmune system: implications for lung cancer cachexia. JCachexia Sarcopenia Muscle, 2022, 13(1): 55-67.
[65] Avancini A, Sartori G, Gkountakos A, et al. Physical Activity andExercise in Lung Cancer Care: Will Promises Be Fulfilled?Oncologist, 2020, 25(3): e555-e569.
[66] Chen HM, Tsai CM, Wu YC, et al. Randomised controlled trialon the effectiveness of home-based walking exercise on anxiety,depression and cancer-related symptoms in patients with lungcancer. Br J Cancer, 2015, 112(3): 438-445.
[67] Mustian KM, Alfano CM, Heckler C, et al. Comparison ofPharmaceutical, Psychological, and Exercise Treatments forCancer-Related Fatigue: A Meta-analysis. JAMA Oncol, 2017, 3(7): 961-968.
[68] Naito T, Mitsunaga S, Miura S, et al. Feasibility of earlymultimodal interventions for elderly patients with advancedpancreatic and non-small-cell lung cancer. J Cachexia SarcopeniaMuscle, 2019, 10(1): 73-83.

相似文献/References:

[1]吴 丹,陈强谱.慢性阻塞性肺疾病相关肌少症的诊断与治疗[J].肠外与肠内营养杂志,2021,(05):308.[doi:10.16151/j.1007-810x.2021.05.010]
　WU Dan,CHEN Qiang-pu.Diagnosis and treatment of chronic obstructive pulmonary disease-related sarcopenia[J].PARENTERAL & ENTERAL NUTRITION,2021,(03):308.[doi:10.16151/j.1007-810x.2021.05.010]
[2]严 玮,叶向红,王 敏,等.1例创伤后多发肠瘘、腹壁缺损并肌少症病儿的治疗与护理[J].肠外与肠内营养杂志,2021,(05):317.[doi:10.16151/j.1007-810x.2021.05.012]
[3]陈新宇,周军良,李婷婷,等.相位角与老年肌少症的关系研究[J].肠外与肠内营养杂志,2021,(05):275.[doi:10.16151/j.1007-810x.2021.05.004]
　CHEN Xin-yu,ZHOU Jun-liang,LI Ting-ting,et al.Association of phase angle with sarcopenia in elderly adults[J].PARENTERAL & ENTERAL NUTRITION,2021,(03):275.[doi:10.16151/j.1007-810x.2021.05.004]
[4]张佩彦,秦肖含,王玉珍.肌少症与肝硬化的研究进展[J].肠外与肠内营养杂志,2022,(01):57.[doi:DOI : 10.16151/j.1007-810x.2022.01.011]
　ZHANG Pei-yan,QIN Xiao-han,WANG Yu-zhen.Research progress of sarcopenia in patients with cirrhosis[J].PARENTERAL & ENTERAL NUTRITION,2022,(03):57.[doi:DOI : 10.16151/j.1007-810x.2022.01.011]
[5]韩 雨,杨 洋,叶向红,等.老年恶性肿瘤病人衰弱与肌少症关系的研究进展[J].肠外与肠内营养杂志,2022,(04):248.[doi:10.16151/j.1007-810x.2022.04.010]
　HAN Yu,YANG Yang,YE Xiang-hong,et al.Research progress on the relationship between frailty and sarcopenia in elderly patients with malignant tumors[J].PARENTERAL & ENTERAL NUTRITION,2022,(03):248.[doi:10.16151/j.1007-810x.2022.04.010]
[6]沈 雷,王俊杰,韩 军,等.胃癌病人术前甲状腺激素水平与肌少症的相关性研究[J].肠外与肠内营养杂志,2022,(05):257.[doi:10.16151/j.1007-810x.2022.05.001]
　SHEN Lei,WANG Jun-jie,HAN Jun,et al.Association of thyroid function with sarcopenia in patients with gastric cancer[J].PARENTERAL & ENTERAL NUTRITION,2022,(03):257.[doi:10.16151/j.1007-810x.2022.05.001]
[7]石培洁,等.应用改良版病人主观综合评估量表诊断肺癌病人营养不良的前瞻性研究[J].肠外与肠内营养杂志,2024,(01):1.[doi:DOI : 10.16151/j.1007-810x.2024.01.001]
　SHI Pei-jie,XIAO Chun-xiu,KANG Chao,et al.A prospective study on the diagnosis of malnutrition in patients with lung cancer by modified patient-generated subjective global assessment[J].PARENTERAL & ENTERAL NUTRITION,2024,(03):1.[doi:DOI : 10.16151/j.1007-810x.2024.01.001]

备注/Memo

备注/Memo:
基金项目 ：国家自然科学基金（71874111，72004133）；上海市“科技创新行动计划”启明星计划（21QA1405300）作者简介 ：董丹妮，在读硕士研究生，主要从事肺癌病人生活质量研究。E-mail：sjtuddn1122@sjtu.edu.cn通讯作者 ：何亚平，E-mail：hypcyr@shsmu.edu.cn
更新日期/Last Update: 1900-01-01